Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD)

End Stage Renal Disease (ESRD) Clinical Trial

Official title:

Performance Evaluation of the AMIA Automated Peritoneal Dialysis (APD) Solution Generation System in Patients Using the AMIA APD Cycler

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03812679
• Other study ID #: BXU011787
• Status: Terminated
• Phase: N/A
• Start date: December 20, 2018
• Est. completion date: February 19, 2020

Study information

• Verified date: July 2021
• Source: Baxter Healthcare Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Peritoneal dialysis (PD) is a well-established treatment for renal failure including long-term management of end stage renal disease (ESRD) by continuous ambulatory peritoneal dialysis or automated peritoneal dialysis (APD).

Complementary therapies offer longer term survival for patients with ESRD. However, none of them are devoid of side effects and today their limitations are better understood by the nephrologist.

The AMIA APD Solution Generation System combines an updated AMIA APD Cycler with Sharesource Platform (previously cleared) with an in-home water system technology and leverages newly developed AMIA APD Concentrates.

The AMIA APD Concentrates, after dilution by the AMIA APD Solution Generation System, are indicated for adult patients in acute or chronic renal failure when non-dialytic medical therapy is judged to be inadequate.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 22
• Est. completion date: February 19, 2020
• Est. primary completion date: February 19, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient is 18 years or older.

2. Patient with ESRD receiving PD therapy, and who is already trained and regularly using the AMIA or HomeChoice APD Cycler with Dianeal PD Solution for at least 12 weeks.

3. Patient is receiving or willing and able to use Dianeal Low Calcium (2.5 mEq/L) PD prescriptive regimen at study treatment initiation per Investigator's assessment.

4. Patient demonstrates adequate PD therapy with clinical euvolemia as assessed by the Investigator with a total Kt/Vurea of a minimum of 1.7 within 45 days of Screening, or measured at Screening. If a total Kt/Vurea is not available within 45 days of Screening, it will be measured at Screening.

5. Investigator assesses that, with appropriate training, the patient will be able to successfully manage his/her dialysis treatments with the AMIA APD Solution Generation System.

6. Patient is available and is willing to complete training on the AMIA APD Solution Generation System.

7. Patient and home environment are deemed suitable for treatment with the AMIA APD Solution Generation System, while in the home.

8. Home electrical and water assessments meet suitability criteria for the AMIA APD Solution Generation System.

9. The patient's home has suitable wireless connection or patient is willing to allow installation of suitable wireless connection.

10. Patient and/or care partner (if participating) is able to read and understand English, and provide informed consent after an explanation of the proposed study. If the patient does not read and understand English, patient may still participate if he/she has a co-residing care partner who reads and understands English, assessed as adequate by the PI.

11. Women of childbearing potential (not menopausal or surgically sterile) must not be pregnant. Serum qualitative and quantitative pregnancy test will be done within 14 days prior to initiation of study product.

• If qualitative serum ß-hCG results are positive, repeat quantitative serum pregnancy test in 48 hours.

• If quantitative serum ß-hCG levels show clinically significant rise within 48 hours, serum progesterone level should be taken. Serum progesterone > 5 ng/mL will exclude a patient from the study.

12. Sexually active males and females agree to use a reliable means of contraception during the study and for 30 days afterwards (e.g., oral contraceptive and condom, intrauterine device and condom, or diaphragm with spermicide and condom).

Exclusion Criteria:

1. Patient with a history of PD catheter dysfunction within 12 weeks prior to study enrollment, as evaluated by the Investigator.

2. Patient who had episodes of peritonitis or exit site infection within 12 weeks prior to study enrollment.

3. Patient who has signs of impending or current infection including a cloudy dialysis effluent or dialysis white cell count > 100/ µL or > 0.1 x 109/ L (after a dwell time of at least 2 hours), with > 50% polymorphonuclear cells, and/or positive dialysis effluent culture.

4. Patient who has a severe primary immune deficiency or other condition that may mask clinical signs of peritonitis, as evaluated by the Investigator.

5. Patient with a history of repeated non-compliance with PD, therapy (e.g., a substantial number of missed clinic visits, missed treatments or a history of mismanagement of diet or medications), as evaluated by the Investigator.

6. Patient who has acute renal failure with the chance for recovery.

7. Patient who is pre-scheduled for a living donor kidney transplant within the next 6 months.

8. Patient who is not expected to live at least 6 months while maintaining PD treatment.

9. Patient who had major abdominal surgery within 6 months prior to study enrollment.

10. Patient with current abdominal hernia, as evaluated by the Investigator.

11. Patient with advanced liver or pulmonary disease, as evaluated by the Investigator.

12. Positive serology test for Hepatitis B Virus or Hepatitis C Virus infection, or aspartate transaminase or alanine aminotransferase > 3 x upper limit of normal at Screening.

13. Patient with diagnosed stage III or IV New York Heart Association (NYHA) heart failure.

14. Patient who has an active malignancy.

15. History of a clinically significant illness and/or clinically significant surgery within the past 14 days preceding the Screening Visit as determined by the Investigator.

16. Patient who is enrolled in another interventional clinical study.

Related Conditions & MeSH terms

• End Stage Renal Disease (ESRD)
• Kidney Diseases
• Kidney Failure, Chronic

Intervention

Device:
• AMIA APD Solution Generation System
The AMIA APD Solution Generation System consists of the AMIA APD Cycler, Sharesource Platform, AMIA APD Concentrates, a disposable set, a bag tray, a Water Softener, and a Water Device (WD).

Locations

Country	Name	City	State
United States	Baxter Investigational Site	Ann Arbor	Michigan
United States	Baxter Investigational Site	Chicago	Illinois
United States	Baxter Investigational Site	Cleveland	Ohio
United States	Baxter Investigational Site	Fitchburg	Wisconsin
United States	Baxter Investigational Site	Jackson	Mississippi
United States	Baxter Investigational Site	Jacksonville	Florida
United States	Baxter Investigational Site	Jonesboro	Arkansas
United States	Baxter Investigational Site	New York	New York
United States	Baxter Investigational Site	New York	New York
United States	Baxter Investigational Site	San Jose	California
United States	Baxter Investigational Site	Temple	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Baxter Healthcare Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Tests Meeting Specifications for the Chemical Composition of Final Dialysis Solution by Visit	The dialysis solution generated by the simulated treatment will be sampled from the heater bag, compared to the specifications of Baxter's approved low calcium Dianeal PD solution. The following 9 test methods will be analyzed: pH at 25 C, Color, 5- (hydroxymethyl)furfural (5HMF), Dextrose hydrous Assay (1.5%, 2.5% or 4.25%), Sodium Lactate Assay, Sodium Assay, Chloride Assay, Magnesium Chloride Hexahydrate (MgCl2.6H2O) Assay, and Calcium Chloride Dihydrate (CaCl2.2H2O) Assay. Measurements were collected using instruments such as meters, chromatography, etc. Data will be reported showing percentage of participants meeting specifications versus percentage of participants not meeting specification. If any one of the values falls outside the limits, then the particular test is considered NOT meeting specifications.	Week 1, 4, 8 and 12
Primary	Percentage of Tests Meeting Specifications for the Microbiological and Chemical Testing of Product Water From Water Device (Pre-sterilizing Filters) by Visit	Microbiological testing within <=0 CFU/mL limit for total aerobic microbial count (TAMC) and total yeast/mold count (TYMC) and <0.03 EU/mL limit for Endotoxins, and chemical parameters. Product water from the WD (pre-sterilizing filters) was collected and tested for microbiological (including endotoxin) contamination per USP <61> and USP <85> and chemical contaminants according to ISO 13959. Chemical parameters include aluminum, copper, fluoride, lead, nitrate, sulphate, zinc, calcium, magnesium, potassium, sodium, antimony, arsenic, barium, beryllium, cadmium, chromium, mercury, selenium, silver, thallium, nickel, cobalt, total chlorine. Chemical measurements were collected using instruments such as meters, chromatography, etc. Data will be reported showing percentage of participants meeting specifications versus percentage of participants not meeting specification. If any one of the values falls outside the limits, then the particular test is considered NOT meeting specifications.	Week 1, 4, 8 and 12
Primary	Percentage of Tests Meeting Specifications for the Microbiological Testing of Product Water From Holding Bag (Post-sterilizing Filters) by Visit	Microbiological testing within <=0 CFU/mL limit for TAMC and TYMC and <0.03 EU/mL limit for Endotoxins. Data will be reported showing percentage of participants meeting specifications versus percentage of participants not meeting specification. If any one of the values falls outside the limits, then the particular test is considered NOT meeting specifications. A test was considered as meeting specifications if all of the following parameters fell within the specified limits: tryptic soy broth growth, fluid thioglycolate growth, and endotoxins. Water in the holding bag was collected and tested for microbiological contamination and endotoxin levels per USP <71> and USP <85>.	Week 1, 4, 8 and 12
Secondary	Change From Baseline in Total Kt/Vurea at Week 5, 6, 7, or 8	Peritoneal dialysis adequacy will be measured by sample collection and calculation of Total Kt/Vurea. Weekly peritoneal Kt/Vurea was calculated from blood and 24-hour PD effluent samples and renal Kt/Vurea was calculated from 24-hour collection of urine samples (if applicable) and blood samples after the patient had been dialyzing with the AMIA APD Solution Generation System for at least 4 weeks. Total Kt/Vurea is the sum of peritoneal Kt/Vurea and renal Kt/Vurea. Note: This secondary efficacy endpoint was measured by sample collection and calculation of total Kt/Vurea, occurring one time during Week 5, 6, 7, or 8 of the Study Treatment Period.	Baseline, Week 5 or Week 6 or Week 7 or Week 8